Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30,284,111
-
Total 13F shares
-
22,805,528
-
Share change
-
+400,975
-
Total reported value
-
$727,049,650
-
Put/Call ratio
-
0.78%
-
Price per share
-
$31.88
-
Number of holders
-
103
-
Value change
-
+$8,072,263
-
Number of buys
-
51
-
Number of sells
-
48
Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q3 2023
As of 30 Sep 2023,
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) was held by
103 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,805,528 shares.
The largest 10 holders included
FMR LLC, BlackRock Inc., ALKEON CAPITAL MANAGEMENT LLC, ORBIMED ADVISORS LLC, VANGUARD GROUP INC, BRAIDWELL LP, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, Candriam S.C.A., and Woodline Partners LP.
This page lists
106
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.